ea0081p646 | Endocrine-Related Cancer | ECE2022
Ferone Diego
, Capdevilla Jaume
, Ang Chan Jennifer
, de Herder Wouter W
, Halperin Daniel
, Mailman Josh
, Singh Simron
, Dorkhan Mozhgan
, Hellstrom Lisa
, Svedberg Agneta
, Tiberg Fredrik
Background: Somatostatin receptor ligands (SRLs) are first-line standard-of-care therapies for gastroenteropancreatic neuroendocrine tumours (GEP-NETs), showing efficacy in tumour and symptom control with an established safety profile. However, disease progression may occur despite standard-dose SRL treatment, requiring more aggressive and toxic treatments. Retrospective/non-randomized data suggest higher-dose SRLs may benefit patients with GEP-NETs who do not respond to stand...